Noteworthy Tuesday Option Activity: TVTX, RDDT, LGND

Reddit Inc. (RDDT) saw 37,406 options contracts trade (≈3.7M underlying shares), roughly 97.7% of its one‑month average daily volume, led by 2,169 contracts in the $130 put expiring Feb 20, 2026 (≈216,900 shares). Ligand Pharmaceuticals (LGND) recorded 1,806 contracts (≈180,600 shares), about 94.1% of its one‑month ADV, with notable activity in the $190 put expiring Jan 16, 2026 (689 contracts, ≈68,900 shares). The flows highlight concentrated put interest at specific strikes and expirations that could reflect hedging or bearish positioning, but the report is descriptive market flow data rather than company fundamental news.

Analysis

Market structure: The outsized put flow in RDDT (37,406 contracts ≈3.7M shares ~97.7% of ADTV) and LGND (1,806 contracts ≈180.6k shares ~94.1% of ADTV) signals concentrated demand for downside protection rather than routine liquidity trades. Market-makers will likely delta-hedge by selling underlying stock into this flow, amplifying short-term downside and volatility; direct beneficiaries are option buyers, short sellers, and liquidity providers collecting premiums, while leveraged long equity holders face forced-markets during expiries (LGND Jan 16 in 3 days, RDDT Feb 20 ~5 weeks).

Risk assessment: Tail risks include idiosyncratic events — a Reddit ad-revenue miss or privacy/regulatory action, and an LGND trial/FDA update — that would cascade through concentrated option exposures and margining. Immediate (days): LGND expiry creates pinning/whipsaw risk; short-term (weeks): RDDT delta-hedging may drive a 5–15% move; long-term (quarters): fundamentals reassert as IV normalizes. Hidden dependencies include whether flows are protective hedges or directional blocks and counterparty concentration at prime brokers. Key catalysts: Jan 16 LGND expiry, Feb 20 RDDT expiry, upcoming earnings/user metrics, FDA announcements.

Trade implications: Tactical plays favor defined-risk bearish exposure on RDDT (limited-cost put spreads) and a wait-for-volatility-crush approach on LGND (avoid directional pre-expiry; buy weakness post-expiry). Rotate out of high-IV small-cap/biotech exposure into lower-beta names or exchange operators (e.g., NDAQ) and hedge systemic tail via 1–3 month S&P put spreads. Monitor put-call skew, near-term IV spikes >50% above 90-day average as triggers to deploy or unwind.

Contrarian angles: Heavy put volume can be hedging for concentrated long portfolios; therefore immediate directional conviction may be overstated and IV could collapse after expiries, creating mean-reversion buys. Historical parallels: option-driven sell-offs (gamma selling) often overshoot by 8–20% then mean-revert within 2–8 weeks; unintended consequences include short-term illiquidity and outsized margin calls that create buying opportunities post-expiry.

Key Decisions for Investors

• RDDT (tactical bearish, defined risk): Establish a 1.5% portfolio position by buying a Feb 20, 2026 $130/$110 put debit spread (buy $130 put, sell $110 put). Rationale: capture downside from delta-hedging while capping loss to premium; exit if spread doubles or RDDT rallies >8% in 10 trading days.
• LGND (event-driven rules-based): Do not open new directional positions before Jan 17, 2026. If LGND gaps down ≥7% on Jan 16 expiry, deploy up to 2% portfolio to buy shares with a 12% stop and a 25% target over 3–6 months. If LGND gaps up and 7–45 day IV collapses >40%, sell 30–45 day strangles sized to 0.5% portfolio to harvest premium.
• Portfolio/sector tilt: Reduce biotech/small-cap high-IV exposure by 1–2% of portfolio and redeploy into low-volatility exchange/market structure names (e.g., NDAQ) or cash. Hedge systemic equity tail by buying a 1% portfolio notional 1–3 month S&P 5%/10% put spread (defined-risk).
• Flow-monitoring triggers: If RDDT $130 put open interest >2x 30-day avg or 1-month IV / 3-month IV ratio >1.5, scale hedges by +0.5% portfolio or add short-term equity shorts; unwind hedges if post-expiry IV compresses >35% within 7 trading days.